United Therapeutics (NASDAQ:UTHR) CEO Sells $4,892,785.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,097,878.29. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Trading Down 2.0%

UTHR stock traded down $10.45 during trading on Thursday, reaching $501.27. The stock had a trading volume of 408,040 shares, compared to its average volume of 493,115. The firm has a fifty day moving average price of $537.88 and a 200 day moving average price of $535.74. The company has a market capitalization of $21.50 billion, a P/E ratio of 17.93, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $6.41 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.32 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Arjuna Capital increased its position in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the last quarter. Sage Rhino Capital LLC grew its holdings in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC increased its holdings in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. raised its position in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its position in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.